AVITA Medical (AVITA Medical) Gross Margin % : 87.35% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is AVITA Medical Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. AVITA Medical's Gross Profit for the three months ended in Dec. 2023 was $12.40 Mil. AVITA Medical's Revenue for the three months ended in Dec. 2023 was $14.20 Mil. Therefore, AVITA Medical's Gross Margin % for the quarter that ended in Dec. 2023 was 87.35%.

The historical rank and industry rank for AVITA Medical's Gross Margin % or its related term are showing as below:

RCEL' s Gross Margin % Range Over the Past 10 Years
Min: 41.23 Med: 75.9 Max: 84.48
Current: 84.48

During the past 13 years, the highest Gross Margin % of AVITA Medical was 84.48%. The lowest was 41.23%. And the median was 75.90%.

RCEL's Gross Margin % is ranked better than
92.96% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.295 vs RCEL: 84.48

AVITA Medical had a gross margin of 87.35% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for AVITA Medical was 11.50% per year.

AVITA Medical Gross Margin % Historical Data

The historical data trend for AVITA Medical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Gross Margin % Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

76.78

79.16

79.65

82.45

84.48

AVITA Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															85.75	84.20	81.25	84.51	87.35

Competitive Comparison of AVITA Medical's Gross Margin %

For the Medical Devices subindustry, AVITA Medical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVITA Medical's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Gross Margin % falls into.

AVITA Medical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

AVITA Medical's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	42.4	/	50.143
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(50.143 - 7.78)	/	50.143
	=	84.48 %

AVITA Medical's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	12.4	/	14.195
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(14.195 - 1.796)	/	14.195
	=	87.35 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

AVITA Medical (NAS:RCEL) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AVITA Medical had a gross margin of 87.35% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

AVITA Medical Gross Margin % Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical (AVITA Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (NAS:RCEL) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

AVHHL:USA 51KA:Germany 51KA:Germany 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.

Executives

James Corbett	director	2 GOODYEAR, IRVINE CA 92618
Jeremy Curnock Cook	director	TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
David D O'toole	officer: CFO	1640 MARENGO STREET, LOS ANGELES CA 90033
Donna Shiroma	officer: General Counsel	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Cary Guy Vance	director	800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
Michael S Perry	director, officer: Chief Executive Officer	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Suzanne Crowe	director	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Jan Stern Reed	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Michael Holder	officer: Chief Financial Officer	6170 RESEARCH RD., STE 103, FRISCO TX 75034
Kathy M. Mcgee	officer: Chief Operating Officer	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Sean Ekins	officer: Sr. VP of Finance	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
David Mcintyre	officer: Chief Financial Officer	SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Damien Mcdonald	director	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Erin Liberto	officer: Chief Commercial Officer	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355